Authorisations of human medicinal products with a new active substance and additional indications 2021

Overview of new authorisations 2021

In the second year of the pandemic, Swissmedic again assessed a record number of medicinal products with new active substances and authorised them for distribution on the Swiss market. In this brochure you can see which procedures the applicants used, how long the authorisation processes lasted, and for which indications the medicines were approved.